DMCC Speciality Chemicals LtdQ1 FY22Chemicals & Petrochemicals

DMCC Speciality Chemicals Ltd

Q1 FY22 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 3

→The company aims to grow but does not provide specific forward-looking numbers.
→New plant commissioning at Dahej is expected to significantly boost sales starting Q2 and beyond.
→Full capacity utilization of new plants is targeted by the end of FY23, depending on market and logistics.
→Specialty chemicals segment saw around 10% volume growth in FY22; growth expected from both old and new products.
→Mature specialty products continue to see growth via new applications and replacing competitors.
→Volume growth targets for specialty chemicals are uncertain; steady volume growth more likely than rapid spikes.
→New CAPEX expected to double previous operational capacity, but with ramp-up periods.
→Export and domestic sales mix expected to expand, with some production dedicated to export markets.
→BORON segment down 20-25% from peak but prospects are improving due to raw material availability.
→Overall growth is linked to successful integration of new capacities, market acceptance, and stable raw material pricing.

Category 3

→The company does not provide explicit forward-looking earnings or EPS guidance.
→They emphasize digesting recent significant investments, especially the new plant at Dahej, before forecasting growth.
→Operating earnings are affected by raw material price volatility; they maintain a pass-through mechanism in contracts to manage margins.
→Specialty chemicals are targeted to grow, but volume growth projections (e.g., 15-20%) are uncertain for mature products.
→New products are achieving planned high margins (~40% EBIT), but pricing and volume growth are subject to market conditions.
→The commissioning of new plants is expected to drive revenue and margin improvement, with full utilization anticipated by FY23 end.
→The company aims to manage working capital and reduce debt as cash flows improve, with no major CAPEX planned until current expansions are digested.
→Overall, cautious optimism about future growth with focus on stability and ramp-up rather than aggressive forward guidance.

3 more insights locked — sign up free to unlock

→The company expects peak debt to increase to around Rs. 100 crores due to ongoing capital expenditure.
→Part of the capital work in progress will be funded internally.
→No specific mention of raising new equity or additional debt beyond the current peak debt estimate.
→The company aims to manage cash flows, reduce debt, and invest in minor projects like energy recovery, but no major CAPEX or fundraising plans are indicated at this time.
→Management's current focus is to digest recent investments and optimize capacity utilization before considering further large investments or fundraising.

→The transcript does not explicitly mention the current or expected order book or pending orders in quantitative terms.
→Bimal Goculdas mentions "market visibility" while discussing plant utilization, implying reasonable confidence in sales ramp-up but does not provide specific orderbook figures.
→The company has significant long-term contracts in specialty chemicals, described as ongoing or perpetual, indicating consistent demand rather than fixed pending orders.
→New capacity expansions (e.g., Dahej plant) are expected to support increased sales, though full utilization is anticipated gradually.
→The company emphasizes customer reliability, contracts with multiple suppliers, and formula-based pricing, but no precise order book size or pending order value is disclosed.

Yes

→The company has completed a significant CAPEX cycle, including commissioning of new plants at Dahej and upgrades at Roha.
→Current CAPEX includes debottlenecking, safety, environmental, and regulatory investments, such as a zero liquid discharge system at Roha.
→Ongoing smaller CAPEX projects include upgrades to fire hydrant systems, effluent treatment, and R&D infrastructure.
→Total CAPEX has faced a cost escalation of about 25-30% due to inflation and supply chain issues.
→No major CAPEX expansions are planned in the near term; focus is on digesting and optimizing existing investments.
→Future investments may include energy recovery projects and potential product expansions once current capacity is fully utilized.
→Debottlenecking efforts are planned, especially in the boron segment, to improve supply and ramp up business.
→R&D expansion planned modestly at Dahej but no major increase at Roha currently.

How does DMCC Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1DMCC Speciality Chemicals Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like DMCC Speciality Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.